Although our findings suggest that G-CSF therapy may reduce the incidence of complications related to cirrhosis in patients with ACLF by approximately 50% compared to those who received SMT, it is important to note that we did not observe statistically significant findings. Here, CSF3 is linked to Cirrhosis.